Literature DB >> 25163683

Impact of RNA-guided technologies for target identification and deconvolution.

Myles Fennell1, Qing Xiang1, Alexia Hwang1, Chong Chen2, Chun-Hao Huang2, Chi-Chao Chen2, Raphael Pelossof3, Ralph J Garippa4.   

Abstract

For well over a decade, RNA interference (RNAi) has provided a powerful tool for investigators to query specific gene targets in an easily modulated loss-of-function setting, both in vitro and in vivo. Hundreds of publications have demonstrated the utility of RNAi in arrayed and pooled-based formats, in a wide variety of cell-based systems, including clonal, stem, transformed, and primary cells. Over the years, there have been significant improvements in the design of target-specific small-interfering RNA (siRNA) and short-hairpin RNA (shRNA), expression vectors, methods for mitigating off-target effects, and accurately interpreting screening results. Recent developments in RNAi technology include the Sensor assay, high-efficiency miR-E shRNAs, improved shRNA virus production with Pasha (DRGC8) knockdown, and assessment of RNAi off-target effects by using the C9-11 method. An exciting addition to the arsenal of RNA-mediated gene modulation is the clustered regularly interspaced short palindromic repeats/Cas9 (CRISPR/Cas) system for genomic editing, allowing for gene functional knockout rather than knockdown.
© 2014 Society for Laboratory Automation and Screening.

Entities:  

Keywords:  CRISPR/Cas9; HCS; OTE; RNAi; deconvolution; functional genomics; pooled shRNA; review; screening; viral vectors

Mesh:

Substances:

Year:  2014        PMID: 25163683     DOI: 10.1177/1087057114548414

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  8 in total

Review 1.  Functional genomic screening approaches in mechanistic toxicology and potential future applications of CRISPR-Cas9.

Authors:  Hua Shen; Cliona M McHale; Martyn T Smith; Luoping Zhang
Journal:  Mutat Res Rev Mutat Res       Date:  2015-01-25       Impact factor: 5.657

Review 2.  Applications of chemogenomic library screening in drug discovery.

Authors:  Lyn H Jones; Mark E Bunnage
Journal:  Nat Rev Drug Discov       Date:  2017-01-20       Impact factor: 84.694

3.  Altered Mitochondria Functionality Defines a Metastatic Cell State in Lung Cancer and Creates an Exploitable Vulnerability.

Authors:  Chen-Hua Chuang; Madeleine Dorsch; Philip Dujardin; Sukrit Silas; Kristina Ueffing; Johanna M Hölken; Dian Yang; Monte M Winslow; Barbara M Grüner
Journal:  Cancer Res       Date:  2020-11-25       Impact factor: 13.312

Review 4.  Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference.

Authors:  Rodolphe Barrangou; Amanda Birmingham; Stefan Wiemann; Roderick L Beijersbergen; Veit Hornung; Anja van Brabant Smith
Journal:  Nucleic Acids Res       Date:  2015-03-23       Impact factor: 16.971

5.  Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute lymphoblastic leukemia.

Authors:  Jennifer L Wilson; Simona Dalin; Sara Gosline; Michael Hemann; Ernest Fraenkel; Douglas A Lauffenburger
Journal:  Integr Biol (Camb)       Date:  2016-06-17       Impact factor: 2.192

Review 6.  Systems Virology and Human Cytomegalovirus: Using High Throughput Approaches to Identify Novel Host-Virus Interactions During Lytic Infection.

Authors:  Chen-Hsuin Lee; Finn Grey
Journal:  Front Cell Infect Microbiol       Date:  2020-06-10       Impact factor: 5.293

7.  Target discovery screens using pooled shRNA libraries and next-generation sequencing: A model workflow and analytical algorithm.

Authors:  Christiane Schaefer; Nikhil Mallela; Jochen Seggewiß; Birgit Lechtape; Heymut Omran; Uta Dirksen; Eberhard Korsching; Jenny Potratz
Journal:  PLoS One       Date:  2018-01-31       Impact factor: 3.240

Review 8.  CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment.

Authors:  Hui Xing; Ling-Hua Meng
Journal:  Acta Pharmacol Sin       Date:  2019-12-02       Impact factor: 6.150

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.